<--- Back to Details
First PageDocument Content
Pharmaceutical industry / Biotechnology / Food and Drug Administration / Monoclonal antibodies / Biosimilar / Biologic / Declaratory judgment / Centocor / Infliximab / Pharmacology / Pharmaceutical sciences / Medicine
Date: 2014-05-29 15:29:36
Pharmaceutical industry
Biotechnology
Food and Drug Administration
Monoclonal antibodies
Biosimilar
Biologic
Declaratory judgment
Centocor
Infliximab
Pharmacology
Pharmaceutical sciences
Medicine

Microsoft Word - 106937148_19

Add to Reading List

Source URL: orangebookblog.typepad.com

Download Document from Source Website

File Size: 159,46 KB

Share Document on Facebook

Similar Documents

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

DocID: 1vhgc - View Document

STATE BIOSIMILAR SUBSTITUTION LAWS Please note: This chart is for informational purposes only and does not constitute legal advice or opinions regarding any specific facts relating to the substitution of biosimilars. You

DocID: 1t1RV - View Document

Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Pharmacology / Biotechnology / Biology / Pharmaceutical sciences / Pharmaceutical industry / Biosimilar / Drugs / Drug discovery / Biopharmaceutical / Clinical trial

27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for

DocID: 1rnQJ - View Document

Business / Biotechnology / Economy / Pharmacy / Pharmaceutical industry / Pharmaceuticals policy / Biopharmaceutical / Pharmaceutical industry in India / Novartis / Biosimilar / Boehringer Ingelheim / Teva Pharmaceutical Industries

January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

DocID: 1rlhw - View Document